Across the United States, cardiovascular disease (CVD) continues to threaten populations. It’s the leading cause of death, with nearly half of all U.S. adults suffering from some form of CVD. Rimidi, a cloud-based software platform that enables personalized management of chronic cardiometabolic conditions across the population has expanded its cloud-based platform to include a view for CVD. Working within the electronic health record (EHR) workflow, clinicians can seamlessly navigate between the
Read More
Companion Medical Integrates Smart Insulin Pen with Rimidi Diabetes Management App
Rimidi and Companion Medical announced a first-of-its-kind partnership to enhance data visualization for clinicians treating high-risk patients with diabetes who are on insulin therapy. The collaboration integrates Companion Medical’s connected device, InPen™, the first and only FDA-cleared, smart insulin pen paired with an integrated diabetes management app, into Rimidi’s platform by pushing insulin dosing data from the InPen through the cloud.Integration BenefitsThis partnership reduces the
Read More
Rimidi, BodyTrace Partner to Provide Cellular-Enabled Scales to Heart Failure Patients
Rimidi has partnered with BodyTrace, a cellular technology company, to provide cellular-enabled scales to heart failure patients who are remotely monitored by their clinicians using Rimidi's software platform. The cellular scales provide a frictionless experience for patients; all they have to do is step on the scale and their weight is automatically transmitted to the Rimidi platform, where their care team can monitor changes in weight that may indicate fluid retention and worsening heart
Read More
Rimidi Raises $6.575M for Cloud-based Enterprise Solution for Diabetes Management
Rimidi, Inc.(formerly known as Rimidi Diabetes), an Atlanta-based digital health startup that provides software and clinical analytics for chronic disease management, announced it has raised $6.575 million in Series A-1 financing, which includes a strategic investment by Eli Lilly and Company, an investment from Turner Investments, and participation from existing investors Cox Enterprises, Village Capital, The Jump Fund, and JAMB Global. The company plans to use the funding round to fuel growth
Read More